Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to reduce the ...

A new peer-reviewed study based on data from nearly 2M individuals highlights a wide range of clinical benefits and risks, ...

Surgery is the gold standard, GLP-1s are all the rage—whether a head-to-head study is needed depends on who you ask.

Reduced risks seen for neurocognitive, coagulation, cardiometabolic disorders; increased risks seen for GI, arthritic disorders ...

Glucagon-like peptide-1 receptor agonists (GLP-1RAs), used to treat diabetes and for weight loss, may be linked with a reduced risk of substance use and neurocognitive disorders, a US study in people ...

Weight loss drugs like Ozempic and Wegovy have been tied in a large, national study to a drop in the risk of developing ...

In one corner, we’ve got Mounjaro, and in the other, Ozempic. They’re both once-a-week injectable drugs designed to help ...

A study on GLP1RA medications found that behavioral side effects likely do not result from direct action on GLP1R.

Allurion stock soars on weight-loss therapy update. Stardust Power breaks ground on Oklahoma lithium refinery. OpenAI ...

(CNN) — Popular GLP-1 medications approved for weight loss, diabetes ... as well as how they compare to treatments that are already available. There’s at least one study underway to try ...